Loading...
XKRX
237690
Market cap1.49bUSD
Jul 09, Last price  
119,200.00KRW
1D
-0.83%
1Q
-16.82%
Jan 2017
165.77%
IPO
170.91%
Name

ST Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:237690 chart
P/E
40.77
P/S
6.76
EPS
2,923.73
Div Yield, %
Shrs. gr., 5y
1.96%
Rev. gr., 5y
21.72%
Revenues
331.55b
+21.11%
138,052,135,210200,361,532,900202,800,435,36297,738,455,80593,256,825,000124,108,664,000165,641,947,000249,321,678,000284,991,652,000273,751,343,000331,552,000,000
Net income
54.99b
+58.42%
25,188,825,08061,425,867,57244,996,926,435-9,267,935,047-18,528,696,000-12,147,164,0003,312,125,00018,000,015,00019,581,190,00034,711,731,00054,991,748,000
CFO
17.50b
-84.01%
35,821,583,86049,589,524,93255,593,624,79512,012,442,144-28,949,923,000-20,701,040,0007,269,873,0007,030,981,0001,298,383,000109,451,358,00017,503,811,000
Dividend
Dec 27, 2024500 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Operating as a Contract Development and Manufacturing Organization (CDMO), ST Pharm Co. Ltd. provides pharmaceutical and non-pharmaceutical products within South Korea. Its comprehensive Chemistry, Manufacturing, and Controls (CMC) services include the development of analytical methods, in-house reference standard testing, qualification and validation of analytical techniques, detailed analytical characterization, and robust CMC documentation. The company also specializes in oligonucleotide-based products, such as antisense oligonucleotides, siRNA, miRNA, aptamers, CpG, and decoy molecules, as well as monomers and phosphoramidites. Additionally, ST Pharm manufactures generic Active Pharmaceutical Ingredients (APIs) for a broad range of therapeutic areas, including anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppression, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medications, along with ingredients for MRI contrast agents. Beyond its pharmaceutical focus, the firm supplies components for secondary batteries, electronic materials, and polymer catalysts. Founded in 1983 as Samchully Pharmaceutical Company Ltd., ST Pharm Co. Ltd. is headquartered in Seoul, South Korea.
IPO date
Jun 23, 2016
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT